Payment overview · 2025
General Payments
$913.02
47 reported records · 12 companies
Healthcare provider profile · identity verified
Yi Ngai, M.D.
Allopathic & Osteopathic Physicians|General Practice · FLUSHING, NY · NPI 1578625737
Verified facts
What the public records show
CMS Open Payments records show Yi Ngai, M.D. received $913.02 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Prolia by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XGEVA as an associated drug or biological on 249 records involving 153 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xgeva by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 337 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $268.13 | 29.4% | 13 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $198.96 | 21.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $111.35 | 12.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.38 | 6.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.49 | 6.1% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $46.03 | 5.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.67 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.31 | 4.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.08 | 4.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.52 | 2.2% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $18.10 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.00 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $913.02 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $229.88 | 11 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $111.35 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $58.38 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.49 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.31 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 337 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 223 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 75 | exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 144 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 137 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
144 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
74 | 49 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | XGEVA open payments reported associated product |
CMS Open Payments — General Payments 249 supporting records · 153 recipient NPIs · example record 1226926773 |
Xgeva · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
337 | 72 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
276 | 53 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
152 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
126 | 126 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
154 | 81 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 24 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
144 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
137 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1854 | 407 |
| Losartan Potassium | Losartan Potassium | 1219 | 240 |
| Vascepa | Icosapent Ethyl | 1193 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 905 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 616 | 123 |
| Raloxifene Hcl | Raloxifene Hcl | 576 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 90 |
| Clopidogrel | Clopidogrel Bisulfate | 407 | 77 |
| Folic Acid | Folic Acid | 406 | 124 |
| Metformin Hcl | Metformin Hcl | 391 | 80 |
| Atenolol | Atenolol | 385 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 344 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 340 | 70 |
| Farxiga | Dapagliflozin Propanediol | 337 | 72 |
| Synjardy | Empagliflozin/Metformin Hcl | 276 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 249 | 51 |
| Calcitriol | Calcitriol | 247 | 56 |
| Xarelto | Rivaroxaban | 225 | 44 |
| Ammonium Lactate | Ammonium Lactate | 224 | 85 |
| Jardiance | Empagliflozin | 223 | 53 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 217 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 212 | 97 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 211 | 43 |
| Omeprazole | Omeprazole | 208 | 90 |
| Gabapentin | Gabapentin | 193 | 66 |
| Finasteride | Finasteride | 186 | 37 |
| Nebivolol Hcl | Nebivolol Hcl | 186 | 32 |
| Donepezil Hcl | Donepezil Hcl | 176 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 40 |
| Carvedilol | Carvedilol | 166 | 35 |
| Fenofibrate | Fenofibrate,micronized | 158 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 156 | 94 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 69 |
| Glipizide Er | Glipizide | 154 | 23 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 154 | 81 |
| Vemlidy | Tenofovir Alafenamide | 152 | 15 |
| Linzess | Linaclotide | 144 | 46 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 139 | 27 |
| Rybelsus | Semaglutide | 137 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 134 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 31 |
| Icosapent Ethyl | Icosapent Ethyl | 132 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 73 |
| Jentadueto | Linagliptin/Metformin Hcl | 131 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 126 | 126 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 33 |
| Alcohol Pads | Alcohol Antiseptic Pads | 119 | 66 |
| Allopurinol | Allopurinol | 108 | 19 |
| Tradjenta | Linagliptin | 101 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 13 |
| Famotidine | Famotidine | 97 | 60 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 95 | 46 |
| Azelastine Hcl | Azelastine Hcl | 92 | 42 |
| Fenofibrate | Fenofibrate | 92 | 22 |
| Methimazole | Methimazole | 92 | 19 |
| Amoxicillin | Amoxicillin | 91 | 68 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 90 | 16 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 89 | 15 |
| Eliquis | Apixaban | 88 | 21 |
| Trintellix | Vortioxetine Hydrobromide | 87 | 21 |
| Mirtazapine | Mirtazapine | 85 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 85 | 16 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 81 | 14 |
| Simvastatin | Simvastatin | 81 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 51 |
| Kerendia | Finerenone | 75 | 14 |
| Potassium Chloride | Potassium Chloride | 74 | 11 |
| Prolia | Denosumab | 74 | 49 |
| Ozempic | Semaglutide | 73 | 12 |
| Myrbetriq | Mirabegron | 71 | 17 |
| Acarbose | Acarbose | 70 | 11 |
| Meloxicam | Meloxicam | 69 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 68 | 18 |
| Montelukast Sodium | Montelukast Sodium | 67 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 12 |
| Ezetimibe | Ezetimibe | 63 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 24 |
| Lisinopril | Lisinopril | 62 | 12 |
| Meclizine Hcl | Meclizine Hcl | 61 | 45 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 12 |
| Azithromycin | Azithromycin | 60 | 57 |
| Valsartan | Valsartan | 60 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 59 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 18 |
| Ketoconazole | Ketoconazole | 55 | 22 |
| Ursodiol | Ursodiol | 54 | suppressed |
| Febuxostat | Febuxostat | 53 | 12 |
| Irbesartan | Irbesartan | 51 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 49 | 45 |
| Celecoxib | Celecoxib | 49 | 27 |
| Telmisartan | Telmisartan | 49 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 48 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 42 |
| Entecavir | Entecavir | 46 | suppressed |
| Hydrocortisone | Hydrocortisone | 46 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 18 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | 16 |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | 31 |
| Entresto | Sacubitril/Valsartan | 42 | 13 |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 24 |
| Mupirocin | Mupirocin | 40 | 29 |
| Loperamide | Loperamide Hcl | 37 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | 12 |
| Furosemide | Furosemide | 36 | 16 |
| Nitroglycerin | Nitroglycerin | 33 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 24 |
| Multaq | Dronedarone Hcl | 32 | suppressed |
| Nexium | Esomeprazole Magnesium | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Clotrimazole | Clotrimazole | 30 | 15 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Metronidazole | Metronidazole | 29 | 18 |
| Mometasone Furoate | Mometasone Furoate | 29 | 16 |
| Acyclovir | Acyclovir | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Procto-Med Hc | Hydrocortisone | 26 | 18 |
| Single Use Swab | Alcohol Antiseptic Pads | 26 | 15 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 24 | 20 |
| Nexletol | Bempedoic Acid | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23 | 21 |
| Cefuroxime | Cefuroxime Axetil | 23 | 22 |
| Diclofenac Epolamine | Diclofenac Epolamine | 23 | 16 |
| Colchicine | Colchicine | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Baclofen | Baclofen | 21 | 16 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Glipizide | Glipizide | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Silodosin | Silodosin | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 15 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | 12 |
| Glipizide Xl | Glipizide | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Proctozone-Hc | Hydrocortisone | 15 | 11 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Xgeva | Denosumab | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Isoniazid | Isoniazid | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $913.02 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CREON, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, Kerendia, Linzess, Ozempic, PROLIA, Rybelsus, TRELEGY ELLIPTA | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error